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doi:10.1016/j.jtcvs.2003.11.0631486 The Journal of Thoracic and CardObjective: Diabetes is considered by some transplant centers to be a relative
contraindication for cardiac transplantation because of concerns regarding decreased
survival, as well as increased incidence of infection and transplant coronary artery
disease. We evaluated our experience with diabetic recipients over the last 10 years.
Methods: From January 1992 through June 2002, 881 patients underwent cardiac
transplantation at New York Presbyterian Hospital. Of these, 161 (18.3%) were
diabetic patients. Diabetic recipients were compared with a control group of 161
nondiabetic recipients matched for age, sex, cause of heart failure, United Network
for Organ Sharing status, and immunosuppression era. Outcome measures included
posttransplantation survival, incidence of infection, rejection, and transplant coro-
nary artery disease.
Results: There was no statistically significant difference in survival between diabetic
and nondiabetic recipients, with actuarial survival at 1, 5, and 10 years of 89.3%,
66.9%, and 45.6%, respectively, for diabetic patients and 87.4%, 78.8%, and 59.1%,
respectively, for nondiabetic patients (P  .168). There was no significant differ-
ence in freedom from infection, rejection, or transplant coronary artery disease
between the groups. By using Cox proportional hazard models, development of
infection, rejection, and transplant coronary artery disease were independent pre-
dictors of decreased survival (P  .001, P  .004, and P  .004, respectively).
Conclusions: These results demonstrate similar short-term and long-term survivals,
as well as similar risks for infection and transplant coronary artery disease, in
diabetic and nondiabetic patients undergoing cardiac transplantation. The trend
toward worse survival in the diabetic cohort, however, raises the possibility that if
a greater number of diabetic patients were evaluated, a significant difference in
survival might be observed, suggesting the need for a multicenter analysis to
validate these outcomes.
Diabetes mellitus (DM) affects 16 million Americans and 150million persons worldwide and is the seventh leading cause ofdeath.1,2 There are 800,000 new cases of diabetes diagnosed eachyear in the United States, with an incidence of 13% and 12%,respectively, in male and female subjects older than 65 years ofage. By the year 2025, the International Diabetes Foundation
predicts that there will be as many as 300 million diabetic patients worldwide.3-5
Diabetic patients have a 4-fold increase in the incidence of ischemic heart
disease, with myocardial infarction being the leading cause of death in this popu-
lation.6-9 Although many centers recommend aggressive surgical intervention for
diabetic patients with coronary artery disease, DM is considered by some transplant
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plantation because of concerns regarding decreased sur-
vival, as well as increased infection, rejection, and trans-
plant coronary artery disease (TCAD).10,11 Furthermore,
there is concern that hyperglycemia will be exacerbated and
more difficult to control because of steroid treatment.12,13
There are several series in the literature that have exam-
ined this issue. However, the total number of diabetic pa-
tients studied in these series is relatively small, and fol-
low-up is limited.14-19 These studies only analyzed short-
term and midterm survival to a maximum of 5 years after
transplantation. Our previously reported experience of 76
diabetic patients, transplanted from January 1995 through
December 1999, demonstrated similar survival, infection,
rejection, and incidence of TCAD for diabetic and nondia-
betic patients, but this study was limited to early and mid-
term (5-year) follow-up.20 The long-term outcome of dia-
betic recipients remains unknown. Our current series of 161
diabetic patients transplanted from January 1992 through
June 2002 addresses this issue by analyzing long-term sur-
vival, development of infection, rejection, and incidence of
TCAD. It represents the largest single-center experience
with long-term (10-year) follow-up and complements our
previously reported series of 76 patients with 5-year follow-
up.
Patients and Methods
We evaluated our experience with diabetic recipients over the last
10 years. From January 1992 through June 2002, 881 patients
underwent cardiac transplantation at New York Presbyterian Hos-
pital–Columbia Medical Center. Of these patients, 18.3% (n 
161) had diabetes, of whom 46.0% (n  74) had type 1 DM, and
54.0% (n  87) had type 2 DM. All patients in the diabetic group
had DM for at least 3 months before cardiac transplantation.
Diabetic recipients were compared with a control group of 161
nondiabetic recipients and matched for age, sex, cause of heart
failure, United Network for Organ Sharing status, and immuno-
suppression era by using strict propensity matching. Outcome
measures included posttransplantation survival and the incidence
of infection, rejection, and TCAD.
Definition of Infection
Posttransplantation infection was defined by the presence of a
positive culture in the blood, respiratory tract, sternum, throat,
urine, stool, or viral-cytomegalovirus in the setting of clinical
symptomatology consistent with infection (fever, abnormal white
blood cell count, or both) and was evaluated in both groups.
Diagnosis and Treatment of Rejection
The degree of rejection was categorized as per the International
Society for Heart Lung Transplantation (ISHLT) Registry biopsy
grading system, with endomyocardial biopsy specimens consistent
with ISHLT Grade 1B or higher considered positive for rejec-
tion.21 Biopsies were performed weekly for the first 4 weeks and
then every 2 weeks for the next month, monthly for 4 months,
every 2 months for the next 6 months, every 3 months for the next
The Journal of Thoracic6 months, and then every 6 to 12 months. Routine treatment of
ISHLT grade 3A or greater rejection consisted of an increase in
oral prednisone to 100 mg/d for 3 days, followed by a taper for 1
week to the baseline dose. If rejection persisted on the basis of a
repeat endomyocardial biopsy or if rejection was accompanied by
altered hemodynamics, intravenous methylprednisolone (1 g daily
for 3 days) was used. Intravenous OKT3 (anti-CD3 monoclonal
antibody; 5 mg/d) was used in 2 conditions: grade 3A/3B or 4
rejection that persisted despite the use of a second intravenous
steroid pulse or rejection with severely compromised hemodynam-
ics. Four weeks after completion of the OKT3 course, antibodies
against murine OKT3 were measured. Patients with titers of anti-
OKT3 antibodies greater than 1:100 and persistent cellular rejec-
tion in the setting of compromised hemodynamics were treated
with antithymocyte globulin (ATGAM). Hemodynamically stable
patients with either persistent grade 3A/3B or 4 rejection despite
multiple courses of steroids, OKT3, and ATGAM or recurrence of
grade 3A/3B rejection within 2 weeks of having completed therapy
with OKT3 or ATGAM were candidates for photopheresis ther-
apy.
Detection of TCAD
All patients underwent annual coronary angiography to evaluate
for TCAD. The diagnosis was based on the following: (1) discrete
lesions resulting in 50% or greater obstruction of the proximal or
middle portion of the major graft vessels or (2) diffuse and con-
centric narrowing of the whole vessels, including their branches.
Reports of “luminal irregularities” were considered positive for
TCAD, whereas reports of “mild tapering of coronary artery” were
considered negative. If a patient had TCAD, the frequency of
angiography was increased to biannually. Patients were not given
routine vasodilators before coronary injections. All angiograms
were reviewed by a cardiologist and compared with the previous
year’s films to detect the presence of luminal irregularities, discrete
stenoses, loss of third-order branches, or pruning of vessels.
Donor Acceptance Criteria
Donors and recipients were matched for ABO blood type compat-
ibility and size (generally within 20% of body weight). Prospective
HLA matching was not used; however, recipients with high levels
of panel-reactive anti-HLA antibodies (20%) underwent a pro-
spective cross-match. Male donors less than 40 years of age and
female donors less than 45 years of age met the criteria as suitable
donors if there was no evidence of preexisting heart disease or
impaired myocardial dysfunction by means of echocardiography.
Older individuals also met the criteria as suitable donors provided
that coronary atherosclerotic lesions could be excluded, ideally by
means of cardiac catheterization. Individuals with serologies pos-
itive for HIV, hepatitis B (hepatitis B sAg), hepatitis C, or non-
primary brain cancer were excluded from being donors.
Graft Procurement
Donor hearts were harvested from beating-heart, brain-dead indi-
viduals. Graft procurement and preservation were performed with
cold University of Wisconsin solution (Viaspan; DuPont Pharma-
ceuticals, Wilmington, Del) and topical hypothermia. Before 1996,
orthotopic cardiac transplantation was performed by using the
22,23biatrial technique described by Lower and Shumway. Since
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bicaval anastomosis technique.24
Immunosuppressive Regimen
There was no difference in the immunosuppression protocol for
diabetic and nondiabetic recipients. Until January 1996, all pa-
tients received cyclosporine (INN: ciclosporin), steroids, and aza-
thioprine. Dosing of cyclosporine consisted of a preoperative oral
dose of 3 to 6 mg/kg, followed by an intravenous dose of 1 to 2
mg/kg every 24 hours until oral intake was tolerated. Daily oral
doses of 3 to 6 mg/kg were adjusted to maintain a serum level of
300 to 350 mg/mL. After 6 to 12 months, cyclosporine doses were
reduced to maintain a serum level between 100 and 150 ng/mL.
Azathioprine was also administered preoperatively as an oral dose
of 4 mg/kg, followed by daily doses of 2 mg/kg, with adjustments
in dosing made on the basis of the patients’ white blood cell count,
platelet count, and hepatic function.
Since January 1996, mycophenolate mofetil, starting at a dose
of 1000 mg twice daily, replaced azathioprine as part of cyclos-
porine-based therapy. Intravenous methylprednisolone (500 mg)
was administered during the operation and postoperatively, with
125 mg given every 8 hours for 3 doses. Prednisone was then
instituted at a daily dose of 1 mg/kg and gradually tapered over 4
months to 0.1 mg · kg1 · d1. Intravenous murine monoclonal
antibody OKT3 (5 mg/d) took the place of cyclosporine for the
first 4 days after transplantation for patients with severe renal
dysfunction. Beginning in 1998, induction therapy with dacluz-
imab was added to our standard immunosuppression regimen in
selected patients.
Exclusion Criteria
Diabetic recipients with severe end-organ damage were not con-
sidered candidates for cardiac transplantation. This included pa-
tients with evidence of retinopathy who were either legally blind or
had undergone previous ocular surgery, nephropathy with serum
creatinine levels of greater than 2.5 mg/dL or urinary protein levels
of greater than 1 g/d, symptomatic orthostasis, or significant pe-
ripheral vascular disease requiring a prior amputation (Table 1).
Diabetic patients with mild or moderate organ dysfunction,
however, did undergo transplantation. This included patients with
retinopathy not requiring an operation, nephropathy with serum
TABLE 1. Inclusion and exclusion criteria for cardiac tran
End-organ damage Excluded (seve
Diabetic retinopathy Blind or history of
ophthalmic surg
Diabetic nephropathy Serum creatinine
2.5 mg/dL or u
protein level 1
Peripheral vasculopathy History of toe or l
extremity ampu
Autonomic dysfunction Symptomatic orth
ABI, Ankle-brachial index.creatinine levels of 2 to 2.5 mg/dL or 24-hour urinary protein
1488 The Journal of Thoracic and Cardiovascular Surgery ● Malevels of 300 mg/d to 1 g/d, peripheral neuropathy, gastroparesis,
and peripheral vascular disease with an ankle-brachial index of
less than 1.0 but no prior history of amputation (Table 1).
Other exclusion criteria for cardiac transplantation not specific
to diabetic patients included the presence of factors that adversely
affect long-term survival (eg, cancer), increase perioperative mor-
bidity and mortality (eg, recent pulmonary embolus or active
infection), or affect a patient’s ability to care for himself or herself
(eg, untreated major psychiatric illness or recent substance abuse).
Pretransplantation severe pulmonary hypertension, defined as
greater than 6 Woods units, was also considered to be a relative
contraindication to transplantation.
Statistical Analysis
Data are presented as frequency distributions and percentages.
Values of continuous variables were expressed as means  SD.
Continuous variables of diabetic patients and control subjects were
compared by using Student unpaired t tests, whereas categoric
variables were compared by means of 2 tests. Kaplan-Meier
analysis was used to calculate survival. Actuarial survival at 1, 3,
5, and 10 years after transplantation was calculated by constructing
life tables. Significant predictors of survival were identified by
using multivariate Cox proportional hazard models. All data were
analyzed with SPSS 11.5 software (SPSS Inc, Chicago, Ill).
Results
Demographics
Recipient data. Table 2 lists the clinical characteristics
of diabetic and nondiabetic patients. There were no signif-
icant differences in age, sex, race, cause of heart failure, or
United Network for Organ Sharing status between the
groups. The diabetic cohort weighed significantly more than
the control subjects (P  .009) and had a greater body mass
index (P  .005). Within the diabetic cohort, 92 (57.1%)
patients demonstrated 1 or more of the clinical manifesta-
tions of mild-to-moderate end-organ damage compared with
82 (50.9%) nondiabetic patients (P  .152). The most
common manifestations of severe end-organ damage that
ntation in diabetic patients with end-organ damage
Included (mild to moderate)
Retinopathy present but not legally
blind and no prior history of
ophthalmic surgery
ry
Serum creatinine level of 2.0-2.5 mg/dL
or urinary protein level of 300 mg/d
1 g/d
ABI 1.0 in either lower extremity
without a prior lower extremity
amputation
is Peripheral neuropathy or gastroparesisspla
re)
ery
level
rina
g/d
ower
tation
ostasformulated the basis for exclusion were severe renal disease
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rate numeric account was unavailable.
Donor data. There was no statistically significant dif-
ference in donor ischemic time (163.0  57.6 minutes for
diabetic patients vs 169.6  61.4 minutes for nondiabetic
patients) or donor age (32.5  12.6 for diabetic patients vs
33.8  13.0 years for nondiabetic patients) between the
groups.
Survival
Overall survival for diabetic and nondiabetic patients is
depicted in Figure 1. There was no significant difference in
survival, although there was a trend toward worse survival
in the diabetic cohort (P  .168). Median survival was 7.8
years for diabetic patients and 9.7 years for nondiabetic
TABLE 2. Clinical characteristics of diabetic and nondia-
betic patients
Variable
Diabetic
patients
Nondiabetic
patients P value†
Recipient data
Age (y) 55.4 10.7* 54.6 10.5 .480
Sex
Male 132 (82.0%) 132 (82.0%) 1.0
Female 29 (18.0%) 29 (18.0%) 1.0
Race
White 118 (73.3%) 129 (80.1%) .147
African American 19 (11.8%) 16 (9.9%) .591
Other 24 (14.9%) 16 (9.9%) .176
Cause of heart failure
CAD 86 (53.4%) 86 (53.4%) 1.0
ICM 65 (40.4%) 65 (40.4%) 1.0
Other 10 (6.2%) 10 (6.2%) 1.0
UNOS status
1 135 (83.9%) 135 (83.9%) 1.0
2 26 (16.1%) 26 (16.1%)
Weight (kg) 78.3 10.7 73.4 11.8 .009
BMI (kg/m2) 26.0 4.4 24.4 5.2 .005
Bridged to transplantation
with LVAD
30 (18.6%) 36 (22.4%) .278
End-organ damage 92 (57.1%) 82 (50.9%) .152
Retinopathy 49 (30.4%) 41 (25.5%) .224
Nephropathy 36 (22.4%) 30 (18.6%) .362
Peripheral
vasculopathy
34 (21.1%) 29 (18.0%) .305
Autonomic dysfunction 14 (8.7%) 8 (5.0%) .183
Donor data
Age (y) 32.5 12.6 33.8 13.0 .364
DIT (min) 163.0 57.6 169.6 61.4 .416
MFM 107 (66.5%) 111 (68.9%) .548
CAD, Coronary artery disease; ICM, idiopathic cardiomyopathy; UNOS,
United Network for Organ Sharing; BMI, body mass index; LVAD, left
ventricular assist device; DIT, donor ischemic time; MFM, male-female
mismatch.
*Mean  SD.
†P values were obtained from paired t tests and 2 tests.patients. Actuarial survival at 1, 5, and 10 years was 89.3%,
The Journal of Thoracic66.9%, and 45.6%, respectively, for diabetic patients com-
pared with 87.4%, 78.8%, and 59.1%, respectively, for
nondiabetic patients. When analyzing only those diabetic
and nondiabetic patients with coronary artery disease as
their cause of heart failure (excluding idiopathic cardiomy-
opathy), survival between the 2 groups was still similar (P
 .190).
There was no significant difference in survival between
patients with type 1 (46.0%, n  74) and type 2 (54.0%, n
 87) diabetes (P  .437). Additionally, there was no
significant difference in short-term or long-term survival
when comparing diabetic patients with and without evi-
dence of mild-to-moderate end-organ damage at the time of
transplantation (P  .242).
Infection
There was no significant difference between diabetic and
nondiabetic patients in the incidence of infection. Freedom
from infection at 1, 3, and 5 years was 86.0%, 42.4%, and
23.9% for diabetic patients and 87.3%, 46.6%, and 31.0%
for nondiabetic patients (P  .632, Figure 2). Although not
statistically significant, diabetic patients were more prone to
becoming bacteremic in the setting of infection, with bac-
teremia developing in 39.5% of diabetic infections com-
pared with 32.3% of nondiabetic infections (P  .074).
The majority of both diabetic (66.3%) and nondiabetic
(58.1%) patients were hospitalized for treatment of their
infection episodes (P  .447) for a mean number of 18.5 
15.1 and 11.2 11.8 days, respectively (P .155). Patients
admitted to the hospital for infection did not have a de-
creased survival compared with those patients with infec-
Figure 1. Long-term survival for diabetic and nondiabetic patients
undergoing cardiac transplantation from January 1992 through
June 2002. DM, Diabetes mellitus.tion not admitted to the hospital.
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There was no significant difference between diabetic and
nondiabetic patients in the incidence of rejection. The over-
all number of rejection episodes per patient was 0.60 0.79
in diabetic patients versus 0.69  0.78 in nondiabetic pa-
tients (P  .304). Freedom from rejection at 1, 3, and 5
years was 85.0%, 45.9%, and 23.1% for diabetic patients
versus 78.5%, 34.0%, and 15.0% for nondiabetic patients (P
Figure 3. Freedom from rejection for diabetic and nondiabetic
patients after cardiac transplantation. There was no significant
difference between the groups in freedom from rejection at 1, 3,
5, and 10 years. DM, Diabetes mellitus.
Figure 2. Freedom from infection for diabetic and nondiabetic
patients after cardiac transplantation. There was no significant
difference between the groups in freedom from infection at 1, 3,
5, and 10 years. DM, Diabetes mellitus. .517, Figure 3). The frequency and duration of hospital-
1490 The Journal of Thoracic and Cardiovascular Surgery ● Maization for rejection episodes was similar for both groups:
34.2% of diabetic patients for 7.8 7.2 days compared with
25.8% of nondiabetic patients for 9.2  5.8 days (P  .129
and P  .944).
TCAD
There was no significant difference between the groups in
freedom from TCAD at 1, 3, and 5 years: 68.4%, 28.4%,
and 13.4% for diabetic patients compared with 68.7%,
31.9%, and 19.6% for nondiabetic patients (P  .240,
Figure 4).
Predictors of Survival
Univariate analysis. By using univariate analysis, the
presence of diabetes was not an independent predictor of
adverse outcome (P  .171). Sex (with male patients dem-
onstrating improved survival over that of female patients, P
 .001), male-female mismatching (P  .022), infection (P
 .001), rejection (P  .002), and TCAD (P  .002) were
significant independent predictors of decreased postopera-
tive long-term survival (Table 3).
Multivariate analysis. By means of multivariate analy-
sis with Cox proportional hazard models, recipient sex (P
.001), infection (P .001), rejection (P .004), and TCAD
(P  .004) were significant risk factors for decreased long-
term survival (Table 4). When isolating each individual
infection type for its effect on survival, only sepsis was
found to significantly decrease survival.
Discussion
Many transplant centers consider DM to be a relative con-
Figure 4. Freedom from TCAD for diabetic and nondiabetic pa-
tients after cardiac transplantation. There was no significant
difference between the groups in freedom from TCAD at 1, 3, 5,
and years. DM, Diabetes mellitus.traindication for cardiac transplantation, even though there
y 2004
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in diabetic patients that have demonstrated similar short-
term and midterm survival for diabetic and nondiabetic
recipients. This might be because these studies analyzed a
relatively small cohort of diabetic patients (n  9-76) and
did not evaluate long-term outcome.14-19 In our previously
reported series of 76 diabetic patients who underwent car-
diac transplantation, we demonstrated similar survival, in-
fection, rejection, and incidence of TCAD for diabetic and
nondiabetic patients.20 However, follow-up time was lim-
ited to 5 years. Our current series of 161 diabetic patients
transplanted from June 1992 through January 2002 provides
long-term (10-year) follow-up on survival, infection, rejec-
tion, and incidence of TCAD. The increased number of
patients in this study has also enabled us to perform a more
extensive statistical analysis, including a Cox regression
multivariate analysis on various factors to identify predic-
tors of survival, as well as to outline inclusion and exclusion
criteria for diabetic patients presenting with manifestations
TABLE 3. Factors affecting survival: Univariate analysis
Variable P value*
Recipient characteristics
Age .711
Sex .001
Race
White .139
African American .081
Other .845
Cause of heart failure
CAD .633
ICM .802
Other .640
Height .089
Weight .071
Obesity .123
BMI .565
Pretransplantation LVAD .614
DM .171
Preoperative creatinine level .753
DIT .346
MFM .022
Donor characteristics
Age .971
Sex .467
Height .583
Weight .425
Postoperative events
Infection .001
Rejection .002
TCAD .002
CAD, Coronary artery disease; ICM, idiopathic cardiomyopathy; BMI, body
mass index; LVAD, left ventricular assist device; DM, diabetes mellitus;
DIT, donor ischemic time; MFM, male-female mismatch; TCAD, transplant
coronary artery disease.
*P value from Cox regression univariate analysis.of end-organ damage at the time of transplantation.
The Journal of ThoracicOur results demonstrate similar perioperative, short-
term, and long-term survival for diabetic and nondiabetic
patients undergoing cardiac transplantation. Furthermore,
the presence of end-organ damage at the time of transplan-
tation did not significantly affect survival within the diabetic
cohort.
Some series have demonstrated a higher incidence of
infection in diabetic patients undergoing cardiac transplan-
tation compared with the incidence in nondiabetic pa-
tients.14 This might be due to their baseline immunocom-
promised state and poor circulation.14 More specifically, the
impairment in antibody response to bacterial antigens and
delay in migration of granulocytes in diabetic patients might
predispose to development of infection.14 In our series,
however, we were unable to corroborate these results. We
found no significant difference between the groups in the
incidence of posttransplantation infection.
However, the increased incidence of associated mortality
from sepsis in diabetic patients raises the following ques-
tions: Should we be more aggressive in our choice of
antibiotic regimens when treating diabetic patients with
infection? Should dosages of immunosuppressants be de-
creased for diabetic patients with infection? A more aggres-
sive antibiotic approach along with a diminution in immu-
nosuppression might limit the magnitude and spread of
infection, allowing diabetic patients to gain local control,
which might decrease the incidence of sepsis and infection-
related death. These questions should be addressed in a
randomized clinical trial, perhaps a multicenter one that
focuses on altering doses of baseline immunosuppressants
and antibiotics in the setting of infection for diabetic pa-
tients after transplantation.
Some series have demonstrated a lower incidence of
rejection in diabetic patients undergoing cardiac transplan-
tation compared with that in nondiabetic patients.25,26 This
might be due to an associated decrease in cell-mediated
immune function in diabetic patients.25,26 Because cardiac
allograft rejection is primarily orchestrated by T cell–me-
diated immune processes, diabetic patients with decreased
cell-mediated activity and responsiveness might exhibit a
TABLE 4. Factors affecting survival by Cox proportional
hazard models
Variable OR 95% CI
P
value SE
Sex 2.372 2.225-2.613 .001 0.255
Infection 2.501 1.540-4.061 .001 0.247
Rejection 1.496 1.308-1.798 .004 0.243
TCAD 1.346 1.168-1.712 .004 0.369
OR, Odds ratio; CI, confidence interval; TCAD, transplant coronary artery
disease.lower incidence of rejection. In our series, however, we did
and Cardiovascular Surgery ● Volume 127, Number 5 1491
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between the groups.
Diabetic and nondiabetic patients demonstrated a similar
incidence of TCAD. This is consistent with other reports in
the literature that have also demonstrated similar incidences
of TCAD in diabetic and nondiabetic patients.15-20 The
latter suggests that TCAD might be more a function of
rejection related to antecedent episodes of acute rejection.
The limitations of this study include those related to a
retrospectively performed analysis. Data were obtained by
means of chart review, which has inherent limitations, such
as access and accuracy of the data. Additionally, although
we demonstrated no statistically significant difference in
survival between diabetic and nondiabetic patients, a trend
toward worse survival in the diabetic cohort raises the
possibility that if a larger cohort of diabetic patients was
studied in a multi-institutional analysis, a statistically sig-
nificant difference in survival might be observed.
In conclusion, our results demonstrate that cardiac trans-
plantation can be performed safely in diabetic patients, with
similar short-term and long-term survival, infection, rejec-
tion, and incidence of TCAD compared with those seen in
nondiabetic patients, although there are limitations in our
study, as described above. Our results do not support mod-
ifying immunosuppression protocols in diabetic patients
undergoing cardiac transplantation. Future studies include
assessing long-term renal function and the requirement for
dialysis in diabetic patients who have undergone heart trans-
plantation. We support liberalization of the transplant crite-
ria and proceeding with transplantation in carefully selected
diabetic patients.
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